Patents Assigned to Memorial Sloan-Kettering Cancer Center
  • Publication number: 20210315868
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: October 14, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic GEISSMANN, Elvira MASS, Rocio VICARIO
  • Patent number: 11141490
    Abstract: Antibody-drug-conjugates (ADC) are provided having a structure of: wherein L is PR3 ligand. The ADC has n drug moieties bound to the Trastuzumab antibody such that the ADC has a drug-to-antibody ratio (DAR) between 2 and 4 and the drug moieties are bound to the Trastuzumab antibody through cysteine (S) or lystine (Lys) residues. The disclosed ADCs are particularly useful in treating breast cancer.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: October 12, 2021
    Assignees: Research Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center
    Inventors: Maria Contel, Natalia Curado, Jason Lewis, Sophie Poty
  • Patent number: 11142797
    Abstract: The presently disclosed subject matter relates to the use of one or more biomarkers to evaluate whether a PI3K? inhibitor would produce an anti-cancer effect in a subject during the course of treatment with a PI3K? inhibitor. It is based, at least in part, on the discovery that certain nucleotides can be isolated from the serum of patients undergoing cancer treatment and can be used as a biomarker to indicate the effectiveness of PI3K treatment on cancer growth. Accordingly, in a non-limiting embodiment, a method for determining whether an anti-cancer effect is likely being produced in a cancer by a PI3K? inhibitor, comprises determining the presence and/or level of one or more PIK3CA biomarkers in one or more samples serially obtained during PI3K? inhibitor treatment, where if the presence and/or level of a PIK3CA biomarker is increased, it is less likely that the PI3K? inhibitor is having an anti-cancer effect on the cancer.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 12, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Mary Ellen Moynahan, Alice Gaskell
  • Publication number: 20210309758
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: July 28, 2020
    Publication date: October 7, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • Patent number: 11136392
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 5, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu
  • Patent number: 11136404
    Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: October 5, 2021
    Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
  • Patent number: 11135320
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: October 5, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Brian Zeglis, Jason Lewis, Thomas Reiner, Jacob Lee Houghton, Jan-Philip Meyer, Christian Brand
  • Publication number: 20210295111
    Abstract: The present disclosure discusses systems and methods to detect blur in digital images. The solution can be incorporated into the quality control systems of pathology and other slide scanners or can be a stand-alone solution. The solution can identify scanned images that include blur and cause the scanner to automatically rescan the blurry image. The solution can also identify regions of the scanned image that include blur. The solution can generate blur maps for each of the scanned images that identify regions of the scanned image that include blur.
    Type: Application
    Filed: December 28, 2020
    Publication date: September 23, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Gabriele CAMPANELLA, Peter J. SCHÜFFLER, Thomas FUCHS
  • Publication number: 20210283248
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: April 25, 2018
    Publication date: September 16, 2021
    Applicants: Adjuvance Technologies, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Philip LIVINGSTON, Govind RAGUPATHI, Jeffrey GARDNER, J Tyler MARTIN
  • Publication number: 20210287797
    Abstract: Described herein are systems and methods of selecting treatment parameters values for treating skin lesions. A device may establish a treatment parameter selection model using a training dataset. The training dataset may include a plurality of examples. Each example may include a sample image of an example skin lesion to which a treatment is administered using an applicator. Each example may include a first label indicating success or failure of the treatment. Each example may include a second label corresponding to treatment parameters defining the treatment. The device may identify an input image. The device may determine that the input image corresponds to a skin lesion based on visual characteristics of the input image. The device may apply the treatment parameter selection model to the input image to output a recommended treatment to apply. The device may store an association between the input image and the recommended treatment.
    Type: Application
    Filed: October 19, 2020
    Publication date: September 16, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Allan C. HALPERN, Steven Q. WANG, Douglas Comrie CANFIELD
  • Publication number: 20210283281
    Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.
    Type: Application
    Filed: July 29, 2017
    Publication date: September 16, 2021
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION, PHLIP, INC.
    Inventors: Jason S. LEWIS, Dustin DEMOIN, Yana K. RESHETNYAK, Oleg A. ANDREEV, Donald M. ENGELMAN, Narissa VIOLA-VILLEGAS
  • Patent number: 11116757
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: September 14, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Patent number: 11120307
    Abstract: Presented herein are systems and methods for feature detection in images. A computing system may identify a biomedical image having features. The computing system may apply the biomedical image to a feature detection model. The feature detection model may include an encoder-decoder block to generate a feature map corresponding to the biomedical image, a confidence map generator having a second set of parameters to generate a confidence map using the feature map, and a localization map generator to generate a localization map using the feature map. The computing system may generate a resultant map based on the confidence map and the localization map. The resultant map identifying one or more points corresponding to the one or more features. The computing system may provide the one or more points identified in the resultant map for the biomedical image.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: September 14, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventor: Chensu Xie
  • Patent number: 11118150
    Abstract: A layered, microfluidic array is disclosed. The array has a first layer with a culture channels extending in a first longitudinal direction. Each culture channel includes multiple traps that entrap cell or tissue samples. The array also has a second layer with microfluidic channels extending in a second longitudinal direction that is orthogonal the first longitudinal direction. A third layer, disposed between the first layer and the second layer, has pores arranged within the third layer such that each nest is vertically stacked above, and fluidly connected with, a corresponding culture chamber in the first layer. Each nest is fluidly isolated from adjacent nests by a fluid impermeable region of the third layer such that horizontal diffusion of water within the third layer is prevented.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: September 14, 2021
    Assignees: Research Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center
    Inventors: Sihong Wang, A. H. Rezwanuddin Ahmed, Xuejun Jiang, Chun-wei Chi, Chenghai Li
  • Patent number: 11117964
    Abstract: The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 14, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Katharine Hsu, Nai-Kong V. Cheung, Su Yan, Yiyang Xu, Jingyi Xiang, Cheng Liu
  • Publication number: 20210275584
    Abstract: Disclosed herein are cells that are immune cells, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, and optionally recombinantly express a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen. In certain embodiments, the immune cell is an immunostimulatory cell, such as a T cell. In certain embodiments, the immune cell is an immunoinhibitory cell, such as a regulatory T cell. Also disclosed herein are immune cells that recognize and are sensitized to a viral antigen, which immune cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell. The cells can be sensitized to an antigen that is a viral antigen. Additionally provided are methods of using such cells to treat a viral infection in a subject in need thereof.
    Type: Application
    Filed: August 29, 2017
    Publication date: September 9, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventor: Prasad S. Adusumilli
  • Patent number: 11109846
    Abstract: An exemplary system, method and computer-accessible medium can include, for example, receiving information related to a scan(s) of a three-dimensional structure(s) containing a first tissue(s) and a second tissue(s), and providing the information to a system for identifying respective tissue types of the first tissue(s) and the second tissue(s). The structure(s) can be scanned to generate the information. The structure(s) can include a paraffin block(s). The first tissue(s) or the second tissue(s) can be excised. The tissue types can include a cancerous tissue and a non-cancerous tissue, and the first tissue(s) can be identified as the cancerous tissue and the second tissue(s) can be identified as the non-cancerous tissue.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 7, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Stephen B. Solomon, Jeremy C. Durack
  • Patent number: 11110297
    Abstract: An apparatus for providing at least one treatment to at least one tissue having a first structural arrangement configured to expand a first portion at a distal end of the apparatus, a second structural arrangement configured to expand a second portion at the distal end and at least one lumen associated with at least one of the first structural arrangement and/or the second structural arrangement. The first structural arrangement and/or the second structural arrangement can be configured to position the at least one lumen at a particular position with respect to the tissue. A tip is configured to aid in the insertion of the apparatus into the tissue(s).
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: September 7, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, GC MEDTECH LLC
    Inventors: Gary A. Lamoureux, Gil'ad N. Cohen, Karyn Goodman
  • Patent number: 11104733
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 31, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu
  • Patent number: 11103531
    Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 31, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Renier J. Brentjens, Hollie J. Jackson